MCTA Charming Medical Limited
Fundamentals / CIK 0002035992 / USDCharming Medical Limited reported $4.81M in revenue and a net loss of $23K for the fiscal year ended March 31, 2026 (down 22.7% year over year), with a 99.3% gross margin and a -0.6% operating margin.
Audited annual (10-K / 20-F) and quarterly (10-Q) statements parsed directly from SEC EDGAR CompanyFacts. Open MCTA in the Convexity terminal for live prices, valuation multiples, transcripts, and insider flow.
-
Revenue FY 2026$4.81M -22.7% YoY
-
Operating Income FY 2026-$29K -0.6% margin
-
Net Income FY 2026-$23K -0.5% net margin
-
Diluted EPS FY 2026$0.00 Split-adjusted
-
Free Cash Flow FY 2026-$1.56M -32.4% FCF margin
-
Cash & ST Investments Mar 31, 2026$4.70M Total debt: $908K
Annual revenue and net income
3 fiscal years (2024 to 2026), reported in USD.
Financial statements and ratios
Reported in USD. Per-share figures and share counts are adjusted for stock splits from SEC filings.
Income Statement (Annual) · Reported in USD · Newest filing period first.
| Income Statement | Mar 31 | Mar 31 | Mar 31 |
|---|---|---|---|
| Revenue | $4.81M | $6.22M | $6.02M |
| Cost of Revenue | $35K | $16K | $11K |
| Gross Profit | $4.77M | $6.21M | $6.00M |
| Total Operating Expenses | $4.84M | $4.83M | $5.01M |
| Operating Income | -$29K | $1.39M | $1.01M |
| EBITDA | $187K | $1.65M | $1.40M |
| Interest Income | $73K | $64K | $20K |
| Interest Expense | $16K | $21K | $26K |
| Income Before Tax | $133K | $1.44M | $1.00M |
| Income Tax Expense | $156K | $236K | $182K |
| Net Income | -$23K | $1.20M | $778K |
| Basic EPS | $0.00 | $0.08 | $0.05 |
| Diluted EPS | $0.00 | $0.08 | $0.05 |
| Basic Shares Outstanding | 16.2M | 15.3M | 15.3M |
| Diluted Shares Outstanding | 16.2M | 15.3M | 15.3M |
Income Statement (Quarterly) · Reported in USD · Newest filing period first.
Balance Sheet (Annual) · Reported in USD · Newest filing period first.
| Balance Sheet | Mar 31 | Mar 31 |
|---|---|---|
| Cash & Cash Equivalents | $4.70M | $817K |
| Cash & Short-Term Investments | $4.70M | $817K |
| Accounts Receivable, Net | $201K | $396K |
| Inventory | $26K | $27K |
| Total Current Assets | $8.17M | $3.37M |
| Property, Plant & Equipment, Net | $607K | $500K |
| Total Non-Current Assets | $1.69M | $1.99M |
| Total Assets | $9.87M | $5.36M |
| Accounts Payable | $17K | $3.5K |
| Short-Term Debt | $186K | $314K |
| Deferred Revenue (Current) | $3.05M | $3.46M |
| Other Current Liabilities | $9.4K | $215K |
| Total Current Liabilities | $4.33M | $4.95M |
| Total Non-Current Liabilities | $356K | $358K |
| Total Liabilities | $4.69M | $5.31M |
| Total Debt (incl. Leases) | $908K | $1.16M |
| Retained Earnings | $97K | $119K |
| Accumulated Other Comp. Income | -$15K | -$3.6K |
| Total Stockholders' Equity | $5.18M | $49K |
| Total Equity | $5.18M | $49K |
Balance Sheet (Quarterly) · Reported in USD · Newest filing period first.
| Balance Sheet | 2026-03-31 | 2025-03-31 |
|---|---|---|
| Cash & Cash Equivalents | $4.70M | $817K |
| Cash & Short-Term Investments | $4.70M | $817K |
| Accounts Receivable, Net | $201K | $396K |
| Inventory | $26K | $27K |
| Total Current Assets | $8.17M | $3.37M |
| Property, Plant & Equipment, Net | $607K | $500K |
| Total Non-Current Assets | $1.69M | $1.99M |
| Total Assets | $9.87M | $5.36M |
| Accounts Payable | $17K | $3.5K |
| Short-Term Debt | $186K | $314K |
| Deferred Revenue (Current) | $3.05M | $3.46M |
| Other Current Liabilities | $9.4K | $215K |
| Total Current Liabilities | $4.33M | $4.95M |
| Total Non-Current Liabilities | $356K | $358K |
| Total Liabilities | $4.69M | $5.31M |
| Total Debt (incl. Leases) | $908K | $1.16M |
| Retained Earnings | $97K | $119K |
| Accumulated Other Comp. Income | -$15K | -$3.6K |
| Total Stockholders' Equity | $5.18M | $49K |
| Total Equity | $5.18M | $49K |
Cash Flow Statement (Annual) · Reported in USD · Newest filing period first.
| Cash Flow Statement | Mar 31 | Mar 31 | Mar 31 |
|---|---|---|---|
| Net Income | -$23K | $1.20M | $822K |
| Depreciation & Amortization | $216K | $263K | $392K |
| Change in Receivables | $194K | -$44K | -$165K |
| Change in Inventory | $1.2K | $1.4K | $38K |
| Operating Cash Flow | -$1.22M | $426K | $295K |
| Capital Expenditure | -$340K | -$288K | -$211K |
| Free Cash Flow | -$1.56M | $138K | $85K |
| Purchases of Investments | -$11K | -$501K | -- |
| Investing Cash Flow | -$179K | -$2.23M | -$211K |
| Financing Cash Flow | $5.29M | $521K | $100K |
| Net Change in Cash | $3.90M | -$1.28M | $185K |
Cash Flow Statement (Quarterly) · Reported in USD · Newest filing period first.
Margins, returns, leverage, liquidity, and year-over-year growth computed directly from SEC EDGAR statement levels. Multi-year figures show cumulative per-share growth.
| Ratios & Growth | Mar 31 | Mar 31 | Mar 31 |
|---|---|---|---|
| Gross Margin | 99.3% | 99.8% | 99.8% |
| Operating Margin | -0.6% | 22.3% | 16.8% |
| Net Profit Margin | -0.5% | 19.3% | 12.9% |
| Return on Equity (ROE) | -0.4% | 2435.0% | -- |
| Return on Assets (ROA) | -0.2% | 22.4% | -- |
| Current Ratio | 1.89x | 0.68x | -- |
| Quick Ratio | 1.88x | 0.68x | -- |
| Debt to Equity | 0.18x | 23.57x | -- |
| Revenue Growth (YoY) | -22.7% | +3.4% | -- |
| Gross Profit Growth (YoY) | -23.1% | +3.4% | -- |
| Operating Income Growth (YoY) | -102.1% | +37.7% | -- |
| Net Income Growth (YoY) | -101.9% | +54.2% | -- |
| EPS Growth (YoY) | -100.0% | +60.0% | -- |
| Operating Cash Flow Growth (YoY) | -385.5% | +44.2% | -- |
| Free Cash Flow Growth (YoY) | -1224.2% | +63.1% | -- |
Quarterly margins, ROE, and ROA use trailing-twelve-month (TTM) flows summed across four contiguous quarters. Growth rates are true year-over-year comparisons against the same quarter a year earlier.